Prostate Cancer Drug Pipeline Update
|出版商||BioSeeker Group AB||商品編碼||171784|
Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth.
There are today 462 companies plus partners developing 469 drugs targeting prostate cancer in development. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 231 drugs. Prostate Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 350 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 335 out of the 339 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 73 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug name & Synonyms
Target Expression Profile
Principal Company & Partners
Target and Molecular Function of Target
Fillings and Approvals
Phase IV Data
Phase III Data
Phase II Data
Phase I Data
Phase 0 Data
Dynamic Report Generator